[시장보고서]일주기 리듬 수면 치료 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

일주기 리듬 수면 치료 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Circadian Rhythm Sleep Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

상품코드 : 1470686

리서치사 : Persistence Market Research

발행일 : 2024년 04월

페이지 정보 : 영문 310 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 6,932,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,124,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 11,789,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

일주기 리듬 수면 치료 시장은 수면 장애에 대한 인식의 증가와 수면 의학의 발전으로 인해 빠르게 발전하고 있는 분야입니다. 이 시장에는 생체시계 교란에 대처하기 위해 고안된 다양한 치료법과 요법이 포함되며, 이는 수면과 각성 주기 및 전반적인 건강에 영향을 미칩니다. 이 보고서는 2024년부터 2031년까지 일주기 리듬 수면 치료 시장의 성장 동인, 잠재적 과제, 새로운 동향을 조사하여 이해관계자 및 의료 전문가에게 귀중한 인사이트를 제공합니다.

세계 일주기 리듬 수면 치료 시장은 예측 기간 동안 꾸준한 성장을 보일 것으로 예상되며, 2024년부터 2031년까지 4.7%의 CAGR을 기록할 것으로 예상됩니다. 시장은 2024년 7억 8,400만 달러에서 2031년 말에는 11억 달러로 확대될 것으로 추정됩니다.

주요 인사이트

추정 시장 가치(2024년) : 7억 8,400만 달러
예상 시장 가치(2031년) : 11억 달러
세계 시장 성장률(2024-2031년 CAGR) : 4.7%

일주기 리듬 수면 치료 시장 - 보고서 범위:

일주기 리듬 수면장애(CRSD)는 현대인의 생활습관 변화와 인공광에 대한 노출 증가로 인해 자연스러운 수면과 각성 주기에 영향을 미치며 점점 더 흔해지고 있습니다. 이러한 장애에는 수면 단계 지연 장애(DSPD), 고도 수면 단계 장애(ASPD), 교대 근무 장애, 시차 장애 등이 포함됩니다. 이 보고서에서는 광치료, 멜라토닌 보충제, 행동치료, 약리학적인 접근법 등 다양한 치료법을 다루며, 이러한 치료법의 범위에 대해 조사합니다.

시장 촉진요인:

일주기 리듬 수면 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 수면 건강의 중요성과 전반적인 웰빙에 미치는 영향에 대한 인식이 높아지는 것이 중요한 촉진요인입니다. 또한, 현대인의 라이프스타일, 스트레스, 업무 관련 요인으로 인한 수면 장애의 유병률 증가는 효과적인 치료법에 대한 수요를 촉진하고 있습니다. 수면 기술과 개인 맞춤형 의료의 발전은 보다 정확한 진단과 맞춤형 치료 접근법을 가능하게 하여 시장 성장을 더욱 촉진하고 있습니다. 웨어러블 수면 추적 장치와 모바일 건강 애플리케이션의 보급 확대는 수면 장애에 대한 인식과 관리의 향상에 기여하고 있습니다.

시장 억제요인:

성장 잠재력이 있는 일주기 리듬 수면 치료 시장은 몇 가지 도전과제에 직면해 있습니다. 일부 치료법, 특히 고도의 기술이나 개별화된 접근법을 필요로 하는 치료법은 높은 비용으로 인해 보급을 저해할 수 있습니다. 또한, 일부 지역에서는 전문 수면 클리닉과 전문가에 대한 접근성이 제한적이라는 점도 시장 성장을 제한할 수 있습니다. 또한, 일주기 리듬 장애에 대한 일반인의 인식 부족은 조기 진단 및 조기 치료를 방해할 수 있습니다. 약리학적 치료의 잠재적 부작용과 수면 보조제에 대한 의존성에 대한 우려도 소비자의 신뢰에 영향을 미칠 수 있습니다.

시장 기회:

일주기 리듬 수면 치료 시장은 많은 혁신과 확장의 기회를 제공하고 있습니다. 기업들은 광 치료 기기 및 수면 추적 웨어러블과 같이 보다 접근하기 쉽고 저렴한 치료 옵션을 개발하는 데 집중할 수 있습니다. 수면 전문가와 기술 기업의 공동 노력은 보다 통합적이고 사용자 친화적인 솔루션으로 이어질 수 있습니다. 원격의료와 가상 진료의 부상은 특히 원격지에서 수면 치료 서비스에 대한 접근성을 확대할 수 있는 기회를 제공합니다. 또한, 수면 건강에 대한 대중의 인식 제고 캠페인의 증가는 조기 진단을 촉진하고 예방 조치를 장려하여 궁극적으로 시장 성장에 기여할 수 있습니다.

소개/주요 조사 결과
과거 시장 규모(금액)와 수량 분석,2019-2023년
시장 규모(금액)와 수량 예측, 2024-2031년
- 디바이스
  - 치료 기기
    - 라이트 박스
    - 데스크 램프
    - 라이트 바이저
    - 새벽 시뮬레이터
  - 진단 장비
    - 액티그래피 센서
    - 손목과 손 밴드형 액티그래피 장비
    - 웨어러블 액티그래피 디바이스
    - 수면다원검사 장비
    - 고정식 수면다원검사 장비
    - 휴대용 수면다원검사 장비
- 약물
  - 벤조디아제핀
  - 비벤조디아제핀계 수면제
  - 오렉신 수용체 길항제
  - 멜라토닌 수용체 작용제
- 크로노세라피
치료 유형별 시장 매력도 분석

제9장 세계의 일주기 리듬 수면 치료 시장 분석과 예측, 장애별

소개/주요 조사 결과
과거 시장 규모(금액) 분석,2019-2023년
시장 규모(금액) 예측, 2024-2031년
- 수면 단계 후퇴 증후군(DSPS)
- 수면상 전진 증후군(ASPS)
- 비24시간 수면각성증후군
- 불규칙수면각성장애(ISWD)
- 교대근무 장애
- 시차 장애
장애별 시장 매력도 분석

제10장 세계의 일주기 리듬 수면 치료 시장 분석과 예측, 유통 채널별

소개/주요 조사 결과
과거 시장 규모(금액) 분석,2019-2023년
시장 규모(금액) 예측, 2024-2031년
- 기관투자가용 판매
  - 재택 케어 환경
  - 웰니스 센터&스파
  - 수면 검사 센터
  - 전문 클리닉
  - 병원
- 소매 판매
  - 소매 약국
  - 드럭스토어
  - 온라인 판매
유통 채널별 시장 매력도 분석

제11장 세계의 일주기 리듬 수면 치료 시장 분석과 예측, 지역별

소개/주요 조사 결과
과거 시장 규모(금액)와 수량 분석,2019-2023년
시장 규모(금액)와 수량 예측, 2024-2031년
- 북미
- 라틴아메리카
- 유럽
- 남아시아
- 동아시아
- 오세아니아
- 중동 및 아프리카
지역별 시장 매력도 분석

제12장 북미의 일주기 리듬 수면 치료 시장 분석과 예측

제13장 라틴아메리카의 일주기 리듬 수면 치료 시장 분석과 예측

제14장 유럽의 일주기 리듬 수면 치료 시장 분석과 예측

제15장 동아시아의 일주기 리듬 수면 치료 시장 분석과 예측

제16장 남아시아의 일주기 리듬 수면 치료 시장 분석과 예측

제17장 오세아니아의 일주기 리듬 수면 치료 시장 분석과 예측

제18장 중동 및 아프리카의 일주기 리듬 수면 치료 시장 분석과 예측

제19장 경쟁 분석

경쟁 대시보드
경쟁에 의한 가격 분석
경쟁 벤치마크
경쟁별 총이익 분석
경쟁 진전
경쟁 상세
- Vanda Pharmaceuticals Inc.
- Natus Medical Incorporated
- Compumedics Ltd.
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company
- Koninklijke Philips NV
- Mylan NV
- Fitbit, Inc
- Garmin Ltd
- Lucimed SA
- RedMed Inc.
- Compass Health Brands(Carex Health)
- Beurer GmbH
- Samarit Medical AG
- Lanaform NV

제20장 사용되는 가정과 두문자어

제21장 조사 방법

ksm

영문 목차

영문목차

The circadian rhythm sleep treatment market is a rapidly evolving sector, driven by increasing awareness about sleep disorders and advancements in sleep medicine. This market encompasses various treatments and therapies designed to address disruptions in the body's internal clock, affecting sleep-wake cycles and overall health. This report delves into the key factors driving growth, potential challenges, and emerging trends in the circadian rhythm sleep treatment market from 2024 through 2031, providing valuable insights for stakeholders and healthcare professionals.

The global circadian rhythm sleep treatment market is expected to experience steady growth during the forecast period, with a projected CAGR of 4.7% from 2024 to 2031. The market is estimated to expand from a value of USD 784 million in 2024 to USD 1.1 billion by the end of 2031.

Key Insights:

Estimated Market Value (2024): USD 784 million
Projected Market Value (2031): USD 1.1 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Circadian Rhythm Sleep Treatment Market - Report Scope:

Circadian rhythm sleep disorders (CRSDs) are becoming more prevalent due to modern lifestyle changes and increased exposure to artificial light, impacting the natural sleep-wake cycle. These disorders include delayed sleep phase disorder (DSPD), advanced sleep phase disorder (ASPD), shift work disorder, and jet lag disorder. The report explores the scope of these treatments, covering various therapies such as light therapy, melatonin supplements, behavioral therapy, and pharmacological approaches.

Market Growth Drivers:

The growth of the circadian rhythm sleep treatment market is driven by several factors. Increasing awareness about the importance of sleep health and its impact on overall well-being is a significant driver. Additionally, the rising prevalence of sleep disorders due to modern lifestyles, stress, and work-related factors fuels the demand for effective treatments. Advances in sleep technology and personalized medicine are enabling more accurate diagnosis and tailored treatment approaches, further boosting market growth. The growing adoption of wearable sleep tracking devices and mobile health applications also contributes to the increased awareness and management of sleep disorders.

Market Restraints:

Despite its growth potential, the circadian rhythm sleep treatment market faces several challenges. High costs associated with some treatments, especially those involving advanced technology or personalized approaches, can deter widespread adoption. Limited access to specialized sleep clinics and professionals in certain regions may also restrict market growth. Additionally, lack of awareness about circadian rhythm disorders among the general population can hinder early diagnosis and treatment. Concerns about the potential side effects of pharmacological treatments and dependency on sleep aids can also affect consumer confidence.

Market Opportunities:

The circadian rhythm sleep treatment market presents numerous opportunities for innovation and expansion. Companies can focus on developing more accessible and affordable treatment options, such as light therapy devices and sleep-tracking wearables. Collaborative efforts between sleep experts and technology companies can lead to more integrated and user-friendly solutions. The rise of telehealth and virtual consultations offers an opportunity to expand access to sleep treatment services, especially in remote areas. Furthermore, increasing public awareness campaigns about sleep health can drive early diagnosis and encourage preventive measures, ultimately contributing to market growth.

Key Questions Addressed in the Report:

What is the Expected Value CAGR of the Circadian Rhythm Sleep Treatment Market?
What is the Revenue Size of the Global Circadian Rhythm Sleep Treatment Market as of 2024-end?
Which Region Held the Largest Market Share in 2024?
Who are the Key Players in the Global Circadian Rhythm Sleep Treatment Market?
What are the Most Effective Treatments for Circadian Rhythm Sleep Disorders?

Competitive Landscape and Business Strategies:

The competitive landscape in the circadian rhythm sleep treatment market features a mix of established pharmaceutical companies and innovative tech startups. Key players like Jazz Pharmaceuticals, Philips Healthcare, and Fitbit offer a range of sleep treatment solutions, from pharmacological therapies to wearable devices. Jazz Pharmaceuticals focuses on developing medications for sleep disorders, including narcolepsy and insomnia. Philips Healthcare offers a variety of sleep-related devices, such as light therapy and continuous positive airway pressure (CPAP) machines. Fitbit, a leader in wearable technology, has integrated sleep tracking features into its fitness devices, enabling users to monitor and improve their sleep patterns.

Key Companies Profiled:

Jazz Pharmaceuticals
Philips Healthcare
Fitbit
ResMed
Takeda Pharmaceuticals
Vanda Pharmaceuticals
Garmin
Zeo Health
Beddit
Casio Computer Co., Ltd.
Medtronic

Circadian Rhythm Sleep Treatment Market Segmentation:

By Treatment Type:

Light Therapy
Melatonin Supplements
Behavioral Therapy
Pharmacological Treatment

By Distribution Channel:

Hospitals and Sleep Clinics
Online Retail
Specialty Pharmacies

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Disorder Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Introduction

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Global Circadian Rhythm Sleep Treatment Market Key Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation Trends
3.3. Innovations & New Launches
3.4. Disease Overview and Epidemiology (Prevalence Data), by Region

4. Global Circadian Rhythm Sleep Treatment Market Key Success Factors

4.1. Product Adoption / Awareness Analysis
4.2. Product Features Vs. Disorder Matrix

5. Global Circadian Rhythm Sleep Treatment Market - Pricing Analysis

5.1. Regional Pricing Analysis
5.2. Pricing Break-Up
- 5.2.1. Manufacturer Level Pricing
- 5.2.2. Distributor Level Pricing
5.3. Global Average Pricing Analysis Benchmark

6. Global Circadian Rhythm Sleep Treatment Market Demand Analysis 2019-2023 and Forecast, 2024-2031

6.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
6.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
6.3. Y-o-Y Growth Trend Analysis

7. Global Circadian Rhythm Sleep Treatment Market Context

7.1. Key Regulations
7.2. Macro-Economic Factors
7.3. Forecast Factors - Relevance & Impact
7.4. Market Dynamics
- 7.4.1. Drivers
- 7.4.2. Restraints
- 7.4.3. Opportunity Analysis

8. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Treatment Type

8.1. Introduction/Key Finding
- 8.1.1. Market Size (US$ Mn) and Volume Share Analysis By Treatment Type
- 8.1.2. Y-o-Y Growth Analysis By Treatment Type
8.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Treatment Type, 2019-2023
8.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Treatment Type, 2024-2031
- 8.3.1. Devices
  - 8.3.1.1. Therapeutic Devices
    - 8.3.1.1.1. Light Box
    - 8.3.1.1.2. Desk Lamps
    - 8.3.1.1.3. Light Visor
    - 8.3.1.1.4. Dawn Simulator
  - 8.3.1.2. Diagnostic Devices
    - 8.3.1.2.1. Actigraphy Sensors
    - 8.3.1.2.1.1. Wrist and Hand band Actigraphy Devices
    - 8.3.1.2.1.2. Wearable Actigraphy Devices
    - 8.3.1.2.2. Polysomnography Devices
    - 8.3.1.2.2.1. Fixed Polysomnography Devices
    - 8.3.1.2.2.2. Portable Polysomnography Devices
- 8.3.2. Drugs
  - 8.3.2.1. Benzodiazepines
  - 8.3.2.2. Nonbenzodiazepine hypnotics
  - 8.3.2.3. Orexin receptor antagonists
  - 8.3.2.4. Melatonin receptor agonist
- 8.3.3. Chronotherapy
8.4. Market Attractiveness Analysis By Treatment Type

9. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Disorder

9.1. Introduction/Key Finding
- 9.1.1. Market Size (US$ Mn) Analysis By Disorder
- 9.1.2. Y-o-Y Growth Analysis By Disorder
9.2. Historical Market Size (US$ Mn) Analysis By Disorder , 2019-2023
9.3. Market Size (US$ Mn) Forecast By Disorder , 2024-2031
- 9.3.1. Delayed Sleep Phase Syndrome (DSPS)
- 9.3.2. Advanced Sleep Phase Syndrome (ASPS)
- 9.3.3. Non-24-h Sleep-Wake Syndrome
- 9.3.4. Irregular Sleep-Wake Disorder (ISWD)
- 9.3.5. Shift Work Disorder
- 9.3.6. Jet Lag
9.4. Market Attractiveness Analysis By Disorder

10. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

10.1. Introduction/Key Finding
- 10.1.1. Market Size (US$ Mn) Analysis By Distribution Channel
- 10.1.2. Y-o-Y Growth Analysis By Distribution Channel
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
10.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2024-2031
- 10.3.1. Institutional Sales
  - 10.3.1.1. Home Care Settings
  - 10.3.1.2. Wellness Centers & Spa
  - 10.3.1.3. Sleep Testing Centers
  - 10.3.1.4. Specialty Clinics
  - 10.3.1.5. Hospitals
- 10.3.2. Retail Sales
  - 10.3.2.1. Retail Pharmacies
  - 10.3.2.2. Drug Stores
  - 10.3.2.3. Online Sales
10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Region

11.1. Introduction/Key Finding
- 11.1.1. Market Size (US$ Mn) and Volume Share Analysis By Region
- 11.1.2. Y-o-Y Growth Analysis By Region
11.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Region, 2019-2023
11.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Region, 2024-2031
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. South Asia
- 11.3.5. East Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region

12. North America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
12.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 12.3.1. By Country
  - 12.3.1.1. U.S.
  - 12.3.1.2. Canada
- 12.3.2. By Treatment Type
- 12.3.3. By Disorder
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Treatment Type
- 12.4.3. By Disorder
- 12.4.4. By Distribution Channel
12.5. Drivers and Restraints: Impact Analysis
12.6. Key Market Participants - Intensity Mapping

13. Latin America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

13.1. Introduction
13.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
13.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 13.3.1. By Country
  - 13.3.1.1. Brazil
  - 13.3.1.2. Mexico
  - 13.3.1.3. Argentina
  - 13.3.1.4. Rest of Latin America
- 13.3.2. By Treatment Type
- 13.3.3. By Disorder
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Treatment Type
- 13.4.3. By Disorder
- 13.4.4. By Distribution Channel
13.5. Drivers and Restraints: Impact Analysis
13.6. Key Market Participants - Intensity Mapping

14. Europe Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
14.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 14.3.1. By Country
  - 14.3.1.1. U.K.
  - 14.3.1.2. Germany
  - 14.3.1.3. France
  - 14.3.1.4. Italy
  - 14.3.1.5. Spain
  - 14.3.1.6. BENELUX
  - 14.3.1.7. Nordic
  - 14.3.1.8. Poland
  - 14.3.1.9. Rest of Europe
- 14.3.2. By Treatment Type
- 14.3.3. By Disorder
- 14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Treatment Type
- 14.4.3. By Disorder
- 14.4.4. By Distribution Channel
14.5. Drivers and Restraints: Impact Analysis
14.6. Key Market Participants - Intensity Mapping

15. East-Asia Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
15.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 15.3.1. By Country
  - 15.3.1.1. China
  - 15.3.1.2. Japan
  - 15.3.1.3. South Korea
  - 15.3.1.4. Rest of East Asia
- 15.3.2. By Treatment Type
- 15.3.3. By Disorder
- 15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Treatment Type
- 15.4.3. By Disorder
- 15.4.4. By Distribution Channel
15.5. Drivers and Restraints: Impact Analysis
15.6. Key Market Participants - Intensity Mapping

16. South Asia Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
16.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Thailand
  - 16.3.1.3. Malaysia
  - 16.3.1.4. Indonesia
  - 16.3.1.5. Philippines
  - 16.3.1.6. Rest of South Asia
- 16.3.2. By Treatment Type
- 16.3.3. By Disorder
- 16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Treatment Type
- 16.4.3. By Disorder
- 16.4.4. By Distribution Channel
16.5. Drivers and Restraints: Impact Analysis
16.6. Key Market Participants - Intensity Mapping

17. Oceania Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
17.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 17.3.1. By Country
  - 17.3.1.1. Australia
  - 17.3.1.2. New Zealand
- 17.3.2. By Treatment Type
- 17.3.3. By Disorder
- 17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Treatment Type
- 17.4.3. By Disorder
- 17.4.4. By Distribution Channel
17.5. Drivers and Restraints: Impact Analysis
17.6. Key Market Participants - Intensity Mapping

18. MEA Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
18.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
- 18.3.1. By Country
  - 18.3.1.1. GCC Countries
  - 18.3.1.2. Iran
  - 18.3.1.3. Israel
  - 18.3.1.4. Turkey
  - 18.3.1.5. Rest of MEA
- 18.3.2. By Treatment Type
- 18.3.3. By Disorder
- 18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Treatment Type
- 18.4.3. By Disorder
- 18.4.4. By Distribution Channel
18.5. Drivers and Restraints: Impact Analysis
18.6. Key Market Participants - Intensity Mapping

19. Competition Analysis

19.1. Competition Dashboard
19.2. Pricing Analysis, By Competition
19.3. Competition Benchmarking
19.4. Gross Margin Analysis, By Competition
19.5. Competition Developments
19.6. Competition Deep Dive
- 19.6.1. Vanda Pharmaceuticals Inc.
  - 19.6.1.1. Overview
  - 19.6.1.2. Product and Disorder Portfolio
  - 19.6.1.3. Production Footprint
  - 19.6.1.4. Sales Footprint
  - 19.6.1.5. Strategy
    - 19.6.1.5.1. Marketing Strategy
    - 19.6.1.5.2. Product Strategy
    - 19.6.1.5.3. Channel Strategy
- 19.6.2. Natus Medical Incorporated
  - 19.6.2.1. Overview
  - 19.6.2.2. Product and Disorder Portfolio
  - 19.6.2.3. Production Footprint
  - 19.6.2.4. Sales Footprint
  - 19.6.2.5. Strategy
    - 19.6.2.5.1. Marketing Strategy
    - 19.6.2.5.2. Product Strategy
    - 19.6.2.5.3. Channel Strategy
- 19.6.3. Compumedics Ltd.
  - 19.6.3.1. Overview
  - 19.6.3.2. Product and Disorder Portfolio
  - 19.6.3.3. Production Footprint
  - 19.6.3.4. Sales Footprint
  - 19.6.3.5. Strategy
    - 19.6.3.5.1. Marketing Strategy
    - 19.6.3.5.2. Product Strategy
    - 19.6.3.5.3. Channel Strategy
- 19.6.4. Teva Pharmaceutical Industries Ltd
  - 19.6.4.1. Overview
  - 19.6.4.2. Product and Disorder Portfolio
  - 19.6.4.3. Production Footprint
  - 19.6.4.4. Sales Footprint
  - 19.6.4.5. Strategy
    - 19.6.4.5.1. Marketing Strategy
    - 19.6.4.5.2. Product Strategy
    - 19.6.4.5.3. Channel Strategy
- 19.6.5. Takeda Pharmaceutical Company
  - 19.6.5.1. Overview
  - 19.6.5.2. Product and Disorder Portfolio
  - 19.6.5.3. Production Footprint
  - 19.6.5.4. Sales Footprint
  - 19.6.5.5. Strategy
    - 19.6.5.5.1. Marketing Strategy
    - 19.6.5.5.2. Product Strategy
    - 19.6.5.5.3. Channel Strategy
- 19.6.6. Koninklijke Philips N.V
  - 19.6.6.1. Overview
  - 19.6.6.2. Product and Disorder Portfolio
  - 19.6.6.3. Production Footprint
  - 19.6.6.4. Sales Footprint
  - 19.6.6.5. Strategy
    - 19.6.6.5.1. Marketing Strategy
    - 19.6.6.5.2. Product Strategy
    - 19.6.6.5.3. Channel Strategy
- 19.6.7. Mylan N.V
  - 19.6.7.1. Overview
  - 19.6.7.2. Product and Disorder Portfolio
  - 19.6.7.3. Production Footprint
  - 19.6.7.4. Sales Footprint
  - 19.6.7.5. Strategy
    - 19.6.7.5.1. Marketing Strategy
    - 19.6.7.5.2. Product Strategy
    - 19.6.7.5.3. Channel Strategy
- 19.6.8. Fitbit, Inc
  - 19.6.8.1. Overview
  - 19.6.8.2. Product and Disorder Portfolio
  - 19.6.8.3. Production Footprint
  - 19.6.8.4. Sales Footprint
  - 19.6.8.5. Strategy
    - 19.6.8.5.1. Marketing Strategy
    - 19.6.8.5.2. Product Strategy
    - 19.6.8.5.3. Channel Strategy
- 19.6.9. Garmin Ltd
  - 19.6.9.1. Overview
  - 19.6.9.2. Product and Disorder Portfolio
  - 19.6.9.3. Production Footprint
  - 19.6.9.4. Sales Footprint
  - 19.6.9.5. Strategy
    - 19.6.9.5.1. Marketing Strategy
    - 19.6.9.5.2. Product Strategy
    - 19.6.9.5.3. Channel Strategy
- 19.6.10. Lucimed S.A.
  - 19.6.10.1. Overview
  - 19.6.10.2. Product and Disorder Portfolio
  - 19.6.10.3. Production Footprint
  - 19.6.10.4. Sales Footprint
  - 19.6.10.5. Strategy
    - 19.6.10.5.1. Marketing Strategy
    - 19.6.10.5.2. Product Strategy
    - 19.6.10.5.3. Channel Strategy
- 19.6.11. RedMed Inc.
  - 19.6.11.1. Overview
  - 19.6.11.2. Product and Disorder Portfolio
  - 19.6.11.3. Production Footprint
  - 19.6.11.4. Sales Footprint
  - 19.6.11.5. Strategy
    - 19.6.11.5.1. Marketing Strategy
    - 19.6.11.5.2. Product Strategy
    - 19.6.11.5.3. Channel Strategy
- 19.6.12. Compass Health Brands (Carex Health)
  - 19.6.12.1. Overview
  - 19.6.12.2. Product and Disorder Portfolio
  - 19.6.12.3. Production Footprint
  - 19.6.12.4. Sales Footprint
  - 19.6.12.5. Strategy
    - 19.6.12.5.1. Marketing Strategy
    - 19.6.12.5.2. Product Strategy
    - 19.6.12.5.3. Channel Strategy
- 19.6.13. Beurer GmbH
  - 19.6.13.1. Overview
  - 19.6.13.2. Product and Disorder Portfolio
  - 19.6.13.3. Production Footprint
  - 19.6.13.4. Sales Footprint
  - 19.6.13.5. Strategy
    - 19.6.13.5.1. Marketing Strategy
    - 19.6.13.5.2. Product Strategy
    - 19.6.13.5.3. Channel Strategy
- 19.6.14. Samarit Medical AG
  - 19.6.14.1. Overview
  - 19.6.14.2. Product and Disorder Portfolio
  - 19.6.14.3. Production Footprint
  - 19.6.14.4. Sales Footprint
  - 19.6.14.5. Strategy
    - 19.6.14.5.1. Marketing Strategy
    - 19.6.14.5.2. Product Strategy
    - 19.6.14.5.3. Channel Strategy
- 19.6.15. Lanaform N.V.
  - 19.6.15.1. Overview
  - 19.6.15.2. Product and Disorder Portfolio
  - 19.6.15.3. Production Footprint
  - 19.6.15.4. Sales Footprint
  - 19.6.15.5. Strategy
    - 19.6.15.5.1. Marketing Strategy
    - 19.6.15.5.2. Product Strategy
    - 19.6.15.5.3. Channel Strategy